Health services research in patients with breast cancer (CAMISS-prospective): study protocol for an observational prospective study

BackgroundThough breast cancer remains a major health problem, there is a lack of information on health care provided to patients with this disease and associated costs. In addition, there is a need to update and validate risk stratification tools in Spain. Our purpose is to evaluate the health services provided for breast cancer in Spain, from screening and diagnosis to treatment and prognosis.MethodsProspective cohort study involving 13 hospitals in Spain with a follow-up period of up to 5 years after diagnostic biopsy. Eligibility criteria: Patients diagnosed with breast cancer between April 2013 and May 2015 that have consented to participate in the study. Data collection: Data will be collected on the following: pre-intervention medical history, biological, clinical, and sociodemographic characteristics, mode of cancer detection, hospital admission, treatment, and outcomes up to 5 years after initial treatment. Questionnaires about quality of life (EuroQoL EQ-5D-5 L, the European Organization For Research And Treatment Of Cancer Core Quality Of Life Questionnaire EORTC QLQ-C30 join to the specific breast cancer module (QLQ-BR23), as well as Hospital Anxiety and Depression Scale were completed by the patients before the beginning of the initial treatment and at the end of follow-up period, 2 years later. The end-points of the study were changes in health-related quality of life, recurrence, complications and readmissions at 2 and 5 years after initial treatment. Statistical analysis: Descriptive statistics will be calculated and multivariate models will be used where appropriate to adjust for potential confounders. In order to create and validate a prediction model, split validation and bootstrapping will be performed. Cost analysis will be carried out from the perspective of a national health system.DiscussionThe results of this coordinated project are expected to generate scientifically valid and clinically and socially important information to inform the decision-making of managers and the authorities responsible for ensuring equality in care processes as well in health outcomes. For clinicians, clinical prediction rules will be developed which are expected to serve as the basis for the development of software applications.Trial registrationNCT02439554. Date of registration: May 8, 2015 (retrospectively registered) .

[1]  G. Bonsel,et al.  Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) , 2011, Quality of Life Research.

[2]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[3]  David Cameron,et al.  Edinburgh Explorer Nottingham Prognostic Index Plus (NPI+): Validation of a clinical decision making tool in breast cancer in an independent series , 2015 .

[4]  E. van Limbergen,et al.  INTERVAL CANCERS IN THE BEGINNING YEARS OF THE BREAST CANCER SCREENING PROGRAMME IN THE BELGIAN PROVINCE OF LIMBURG , 2008, Acta clinica Belgica.

[5]  V. Gebski,et al.  Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone , 2013, SpringerPlus.

[6]  S. Cross,et al.  PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2 , 2012, British Journal of Cancer.

[7]  Álvaro Zapico Goñi,et al.  Health related quality of life improvement in breast cancer patients: secondary outcome from a simple blinded, randomised clinical trial. , 2015, Breast.

[8]  M. J. van de Vijver,et al.  External Validation of Adjuvant! Online Breast Cancer Prognosis Tool. Prioritising Recommendations for Improvement , 2011, PloS one.

[9]  N. Aaronson,et al.  The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Charles E McCulloch,et al.  Relaxing the rule of ten events per variable in logistic and Cox regression. , 2007, American journal of epidemiology.

[11]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[12]  Prevalence of persistent pain after breast cancer treatment by detection mode among participants in population-based screening programs , 2016, BMC Cancer.

[13]  G. Huston The Hospital Anxiety and Depression Scale. , 1987, The Journal of rheumatology.

[14]  C. Velde,et al.  Impact of comorbidity on outcome of older breast cancer patients: a FOCUS cohort study , 2014, Breast Cancer Research and Treatment.

[15]  G. Collins,et al.  New Guideline for the Reporting of Studies Developing, Validating, or Updating a Multivariable Clinical Prediction Model: The TRIPOD Statement , 2015, Advances in anatomic pathology.

[16]  F. Arias,et al.  The eortc QLQ‐C30 (version 3.0) quality of life questionnaire: validation study for Spain with head and neck cancer patients , 2002, Psycho-oncology.

[17]  N Houssami,et al.  Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI. , 2012, Breast.

[18]  W. Shen,et al.  Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer , 2016, Health and Quality of Life Outcomes.

[19]  R Holland,et al.  European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition--summary document. , 2008, Annals of Oncology.

[20]  H. Johansson,et al.  Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer , 2012, Medical Oncology.

[21]  R. Cress,et al.  Comorbidity Burden and Guideline‐Concordant Care for Breast Cancer , 2014, Journal of the American Geriatrics Society.

[22]  J. Valderas,et al.  Impact of Undetected Comorbidity on Treatment and Outcomes of Breast Cancer , 2014, International journal of breast cancer.

[23]  I. Arostegui,et al.  Evaluation of the psychometric characteristics of the Spanish version of the Hospital Anxiety and Depression Scale , 2003, Acta psychiatrica Scandinavica.

[24]  Consumer Protection,et al.  European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition--summary document. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  M. Basterretxea,et al.  Supervivencia relativa en cáncer de mama después de la primera recidiva y factores pronóstico asociados , 2009 .

[26]  Kevin A. Henry,et al.  Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State , 2015, Journal of the National Cancer Institute.